Equities researchers at StockNews.com began coverage on shares of Conformis (NASDAQ:CFMS – Get Rating) in a research note issued to investors on Wednesday. The brokerage set a “hold” rating on the medical instruments supplier’s stock.
Conformis Stock Performance
Shares of CFMS stock opened at $1.46 on Wednesday. The company has a debt-to-equity ratio of 0.38, a quick ratio of 4.29 and a current ratio of 5.63. Conformis has a one year low of $1.07 and a one year high of $13.75. The company’s 50-day simple moving average is $1.57 and its 200-day simple moving average is $1.98. The stock has a market capitalization of $10.95 million, a price-to-earnings ratio of -0.21 and a beta of 1.10.
Hedge Funds Weigh In On Conformis
Large investors have recently modified their holdings of the stock. Virtu Financial LLC bought a new position in shares of Conformis during the first quarter worth about $40,000. Bank of New York Mellon Corp lifted its position in shares of Conformis by 2.3% during the third quarter. Bank of New York Mellon Corp now owns 368,020 shares of the medical instruments supplier’s stock worth $71,000 after purchasing an additional 8,191 shares during the last quarter. Jane Street Group LLC acquired a new stake in Conformis during the second quarter worth about $84,000. Dimensional Fund Advisors LP acquired a new stake in Conformis during the fourth quarter worth about $91,000. Finally, MYDA Advisors LLC acquired a new stake in Conformis during the third quarter worth about $133,000.
Conformis Company Profile
ConforMIS, Inc is a medical technology company, which engages in the development, manufacture, and sale of joint replacement implants. It operates through the following geographical segments: United States, Germany, and Rest of the World. The firm’s products include iUni, iDuo, iTotal CR, and iTotal.
Read More
- Get a free copy of the StockNews.com research report on Conformis (CFMS)
- Do Bank Stocks Go Up When Interest Rates Rise?
- How to Invest in Vertical Farming Stocks
- Can-Fite BioPharma Spikes on Pancreatic Cancer Inhibition Finding
- Ecolab: Slow And Steady Wins The Race
- MGM’s Hot Hand Is All In For A Rally, After This Small Break
Receive News & Ratings for Conformis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conformis and related companies with MarketBeat.com's FREE daily email newsletter.
